Mill Capital Management’s GSK GSK Stock Holding History

Mill Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,719	Closed	-$202K	–	130
2022 Q2	$202K	Hold	3,719	–	–	0.02%	119
2022 Q1	$203K	Buy	+3,719	New	+$202K	0.02%	124

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Mill Capital Management's GSK Position: Q3 2022 in Review

Mill Capital Management sold out of GSK (GSK) in Q3 2022, closing a stake of 3,719 shares — an estimated $202K sold.

Mill Capital Management first reported a position in GSK in Q1 2022 and held it in 2 quarters. The position peaked at $203K in Q1 2022. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.

Mill Capital Management reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
Mill Capital Management sold 3,719 GSK shares in Q3 2022, an estimated $202K.
Mill Capital Management first reported a position in GSK in Q1 2022 and held it in 2 quarters.
Mill Capital Management's GSK position peaked at $203K in Q1 2022.
742 funds tracked by Wall St. Rank held GSK as of Q3 2022.

Based on Mill Capital Management's 13F filing for Q3 2022, filed 18 Oct 2022.